Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 136,942 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 136,942 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66. Following the sale, the insider directly owned 18,630,739 shares in the company, valued at $684,307,043.47. This trade represents a 0.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total transaction of $10,320,628.75.

Roivant Sciences Stock Up 3.1%

Shares of ROIV traded up $1.13 during mid-day trading on Tuesday, hitting $37.37. 6,409,504 shares of the company’s stock traded hands, compared to its average volume of 5,396,372. The business’s 50-day moving average price is $34.16 and its 200-day moving average price is $30.17. Roivant Sciences Ltd. has a 1 year low of $11.54 and a 1 year high of $37.46. The firm has a market capitalization of $26.99 billion, a P/E ratio of -70.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Sell-side analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG lifted its stake in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares during the period. Morgan Stanley raised its stake in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after buying an additional 14,036,696 shares during the period. Goldman Sachs Group Inc. grew its stake in Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after acquiring an additional 8,621,567 shares during the period. Norges Bank purchased a new stake in Roivant Sciences in the 4th quarter worth $112,750,000. Finally, Jefferies Financial Group Inc. purchased a new position in Roivant Sciences during the fourth quarter valued at $76,272,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ROIV. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Citigroup lifted their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research note on Thursday, August 6th. Finally, HC Wainwright upped their price target on Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average target price of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.